IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5812-5817

  Rodolfo, Monica ^a   Melani, Cecilia ^a   Zilocchi, Chiara ^a   Cappetti, Barbara ^a   Luison, Elena ^a   Arioli, Ivano ^a   Parenza, Mariella ^a   Canevari, Silvana ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 4; RECEPTOR; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGENICITY; IMMUNOTHERAPY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CANCER VACCINES; FEMALE; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-4; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; VACCINATION;

EID: 0032535410     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sahin, U., Tureci, O., and Pfreundshuh, M. Serological identification of human tumor antigen. Curr. Opin. Immunol., 9: 709-716, 1997.
2. Old, L. J., and Chen, Y. New paths in human cancer serology. J. Exp. Med., 187: 1163-1167, 1998.
3. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
4. Jager, E., Chen, Y., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., and Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 2: 265-270, 1998.
5. Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., and Cheever, M. A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol., 15: 3363-3367, 1997.
6. Schulz, K. R., Knarnet, J. P., Gieni, R. S., Hayglass, K. T., and Greenberg, P. D. The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science (Washington DC), 249: 921-923, 1990.
7. Qin, Z., and Blankenstein, T. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the anti-tumor response. Cancer Res., 55: 4747-4751, 1995.
8. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to produce IL-4. J. Immunol., 153: 5659-5673, 1994.
9. Feldman, J. D. Immunological enhancement: a study of blocking antibodies. Adv. Immunol., 15: 167-214, 1972.
10. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., and Blankenstein, T. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med., 4: 627-630, 1998.
11. Livingston, P. O., and Ragupathi, G. Carbohydrate vaccines that induce antibodies against cancer. Previous experience and future plans. Cancer Immunol. Immunother., 45: 10-19, 1997.
12. Miller, K., Abeles, G., Oratz, R., Zeleniuch-Jacquotte, A., Cui, J., Roses, D. F., Harris, M. N., and Bystryn, J. C. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer (Phila.), 75: 495-502, 1995.
13. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of Self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med., 182: 1606-1614, 1995.
14. Naftzger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradi, S., and Houghton, A. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA, 93: 14809-14814, 1996.
15. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
16. Pardoll, D. Cancer vaccines. Nat. Med., 4: 525-531, 1998.
17. Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P. L., and Forni, G. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today, 18: 32-36, 1997.
18. Rodolfo, M, Zilocchi, C., Melani, C., Cappetti, B., Arioli, I., Parmiani, G., and Colombo, M. P. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol., 157: 5536-5542, 1996.
19. Coney, L. R., Tommassetti, A., Carayannopoulos, L., Frasca, V., Kamen, B. A., Colnaghi, M. I., and Zuraski, V. R. Cloning of a tumor-associated antigen: Mov18 and Mov19 antibodies recognize a folate-binding protein. Cancer Res., 51: 6125-6132, 1991.
20. Stavnezer, J. Immunoglobulin class switching. Curr. Opin. Immunol., 8: 199-205, 1996.
21. Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G., Pupa, M. S., Regazzoni, M., Tagliabue, E., and Colnaghi, M.I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39: 297-303, 1987.
22. 2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int. J. Cancer, 62: 643-650, 1995.